Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2MCash, Jun 2026
1moCash Runway (est.)
+35%Share Count, 1 Year
Follow NTHI by emailGet an email when NTHI pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NTHI, unsubscribe in one click. Privacy
📣 What NTHI Says Is Next
this year · “For NEO100, our fully enrolled Phase 2a study in recurrent IDH1-mutant high-grade glioma continues progressing toward an anticipated interim data readout later this year.”
Company press release, May 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
NTHI reported $2M in cash and short-term investments (as of Jun 30, 2026) and used about $5.9M/quarter in operations, an estimated runway of 1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:54 · Elevated
Cash runway 1 months +40
Shelf registration (S-3, Apr 2026) +10
Share count +35% in a year +14
Raised after last reported balance sheet (Sep 2026) -10
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NTHI and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.